New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that ...

Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

MedtechWOMEN today announced the theme of its upcoming MedtechVISION 2025 Annual Conference, "Revolution not Evolution: Medtech’s Next Chapter", signaling a bold call to action—urging the medtech ...

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...